Observational studyAnnals of the rheumatic diseases2026
Oral glucocorticoid treatment for checkpoint inhibitor-associated inflammatory arthritis does not affect cancer progression-free survival: a RADIOS Registry study.
Observational study in Annals of the rheumatic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Balancing immunosuppression and cancer survival in the treatment of immune checkpoint inhibitor-associated inflammatory arthritis.EULAR rheumatology open · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
objectivesGlucocorticoids are the first-line treatment for immune checkpoint inhibitor-associated inflammatory arthritis (ICI-IA). However, glucocorticoids may negatively impact cancer progression-free survival (PFS). We investigated the association between glucocorticoids and PFS among patients with cancer with ICI-IA.
methodsData from the prospective multicentre rheumatic adverse events due to Immunotherapy Observational Study registry were used. Kaplan-Meier plots and multivariable Cox regression models (time-varying and landmark) assessed glucocorticoid dose and its association with PFS. Participants who progressed before glucocorticoid initiation were excluded from the landmark analysis.
resultsParticipants with ICI-IA (N = 269) had a mean age of 64.85 years (SD: 12.87), 48.3% were female, 87% were White, 32% had melanoma, and most were stage IV (56.4%). In the first month of treatment, the median glucocorticoid dose (prednisone equivalent) was 13 mg daily and 7.8% of participants received an immunomodulatory disease-modifying antirheumatic drug. Cancer progression occurred in 67 participants (24.9%). In a time-varying Cox model, glucocorticoids were not associated with PFS (adjusted hazard ratio [aHR]: 2.64 [95% CI: 0.36-19.61]). Glucocorticoid doses above the median compared with below the median in the first month of ICI-IA treatment were not associated with worse PFS in adjusted Cox models (aHR: 1.15 [95% CI: 0.59-2.25]).
conclusionsIn this prospective ICI-IA cohort, low doses of glucocorticoids (median dose 13 mg [IQR: 7.5, 25] in the first month of treatment) did not adversely affect PFS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.